bluuebunny/crossref_metadata_2025_split huggingface dataset:
Molecular cloning of a lamprey homologue of the mammalian MHC class III gene, complement factor B.
Authors: Nonaka M , Takahashi M , Sasaki M 
Published: December 2022

Abstract
To elucidate the origin and evolution of the complement system and the MHC, we isolated cDNA clones for the MHC class III complement factor B (Bf) gene from lamprey, one of the most primitive extant vertebrates. A part of the serine protease domain of the lamprey Bf was amplified by reverse transcriptase-PCR using the degenerated primers corresponding to the conserved amino acid stretches between the mouse Bf and C2 sequences. A full-length lamprey Bf cDNA clone was isolated from the lamprey liver cDNA library using a PCR-amplified DNA clone as a probe. The deduced amino acid sequence of 763 residues showed essentially the same domain structure as mammalian Bf or C2, consisting of three short consensus repeat domains, a von Willebrand domain, and a serine protease domain. Lamprey Bf showed 33 and 29% overall amino acid similarity to mouse Bf and mouse C2, respectively, whereas amino acid similarity between mouse Bf and mouse C2 was 36%, suggesting that the gene duplication of Bf/C2 occurred in the main line of vertebrate evolution after the divergence of cyclostomes. This is the first report of the molecular cloning from cyclostomes of a component of the mammalian MHC that offers the possibility of genetic analysis of the presumably primitive MHC of cyclostomes.
In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Authors: Siegall C B , Chace D , Mixan B , Garrigues U , Wan H , Paul L , Wolff E , Hellström I , Hellström K E 
Published: December 2022

Abstract
BR96 sFv-PE40 is a single-chain immunotoxin fusion protein targeted to the Ley Ag, which is expressed in many different human carcinomas as well as in normal gastrointestinal epithelium of humans and certain animals, including athymic rats but not mice. In vitro binding analysis determined that BR96 sFv-PE40 was similar in affinity to BR96 Fab. BR96 sFv-PE40 internalizes rapidly, similar to BR96 IgG. H3396 cells, derived from metastatic human breast carcinoma, have been established as tumor xenografts in estradiol-supplemented athymic mice and rats. H3396 tumor xenografts established in athymic mice (up to 350 mm3) and rats (up to 100 mm3) completely regressed after i.v. administration of BR96 sFv-PE40, given as 0.625 mg/kg (1.975 mg/m2) every 4th day for a total of five doses (mice) or 0.25 mg/kg (1.475 mg/m2) every 4th day for a total of four doses (rats). The tumors remained regressed for the duration of the study (&gt; 85 days post-implant), which represents &gt; 10 doubling times, indicating that the animals were cured. There was no toxicity in rats receiving a curative dose of 0.25 mg/kg, although liver and lung toxicity could be detected at a 16 times higher dose, 4 mg/kg or 23.6 mg/m2. We conclude, therefore, that BR96 sFv-PE40 can cure tumor xenografts at well tolerated doses and also in the presence of Ley expression in normal tissues.
Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Authors: Yoshino I , Peoples G E , Goedegebuure P S , Maziarz R , Eberlein T J 
Published: December 2022

Abstract
To study potential sources of tumor-associated Ags in human ovarian cancer, we have established two ovarian tumor cell lines (OvS1 and OvA2) from two ovarian cancer patients, which express the cellular oncogene HER2/neu. Corresponding tumor infiltrating lymphocyte cultures have also been established and display an autologous tumor-specific pattern of cytotoxicity that is HLA-A2 restricted. To determine the potential relationship between HER2/neu expression and CTL-mediated cytolysis, we first established tumor cell clones from OvS1. These were categorized as high or low expressors of HER2/neu (cOvS1+ or cOvS1-, respectively), and cOvS1+ clones displayed a significantly higher sensitivity to CTL killing as compared with cOvS1- clones. To modulate the expression of HER2/neu, ovarian cancer cells were treated with IFN-gamma. After this exposure, HER2/neu expression was significantly decreased, whereas the expression of HLA Class I was significantly increased. Despite the increase in HLA Class I molecules on the cell surface, CTL-mediated cytolysis of both OvS1 and OvA2 was significantly decreased. IFN-gamma treated cOvS1+ clones displayed a similar decrease in sensitivity to CTL killing, whereas IFN-gamma treated cOvS1- clones displayed an increase or no change in sensitivity to CTL. To confirm this apparent association between HER2/neu expression and CTL recognition, melanoma tumor cell lines that were insensitive to ovarian tumor-specific CTL were transfected with the HER2/neu gene. An HLA-A2+ HER2/neu-transfected melanoma cell line was made sensitive to HLA-A2 restricted ovarian tumor-specific CTL but not to HLA-A2 unrestricted CTL, whereas an HLA-A2- HER2/neu-transfected melanoma remained insensitive to HLA-A2 restricted CTL. These results demonstrate that the sensitivity of ovarian epithelial tumor cells to CTL-mediated lysis is associated with the level of expression of HER2/neu, suggesting that this oncogene product may serve as a source of tumor-associated Ags or as an inducer of such peptides. This is the first time in a human tumor system that oncogene expression has been related to the induction of antigenicity. These results prompt us to approach new strategies for immunotherapy of cancer.
Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides.
Authors: Chou Y K , Morrison W J , Weinberg A D , Dedrick R , Whitham R , Bourdette D N , Hashim G , Offner H , Vandenbark A A 
Published: December 2022

Abstract
The biased expression of V beta 5.2 and V beta 6.1 by T cells specific for myelin basic protein (BP) has led to our use of TCR peptides from these V gene sequences to induce anti-TCR immunity in patients with multiple sclerosis (MS). Injection of V beta 5.2-39-59 or V beta 6.1-39-59 peptides significantly increased the peptide specific T cell frequency in 7 of 11 MS patients, often with an accompanying delayed hypersensitivity reaction at the injection site. Here, we validate these cellular immune responses by characterizing TCR peptide specific T cells from an MS patient with biased V beta 5.2 expression in BP reactive T cells before treatment with TCR peptides, and from two MS patients in whom the frequencies of anti-TCR peptide specific T cells were significantly boosted after injection with low doses of TCR peptides. In both cases, T cell lines were established with relative ease, especially after boosting with the peptides. A V beta 5.2-39-59 reactive line responded selectively to the boosting peptide and was restricted by both MHC class I (HLA-B7) and MHC class II (HLA-DR2) molecules. Characterization of 22 clonal isolates revealed that the responding T cells were predominantly activated CD4+CD8lo, circulating memory cells restricted by either HLA-B7 or HLA-DR2, that utilized mainly V beta 4, V beta 6, V beta 12, and V beta 14, but not V beta 5.2 in their TCR. T cell isolates specific for V beta 6.1-39-59 possessed similar characteristics but contained specificities cross-reactive with an N-terminal sequence on V beta 5.2-39-59. Upon stimulation with peptide or Con A, the TCR peptide specific T cell lines had increased message production for IFN-gamma, GM-CSF, IL-4, IL-5, and to a lesser degree, IL-2. This lymphokine mRNA profile differed from a BP-specific T cell line that produced message for IFN-gamma and GM-CSF but low or absent levels of IL-4 and IL-5. The extensive parallels between human T cells specific for V beta 5.2 and V beta 6.1 CDR2 peptides and rat T cells specific for V beta 8.2 CDR2 peptide that are highly protective against experimental encephalomyelitis strengthen the rationale for the therapeutic use of TCR peptides in human autoimmunity.
Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells.
Authors: Thomas R , Davis L S , Lipsky P E 
Published: December 2022

Abstract
Monocytes and dendritic cells (DC) can be purified from fresh peripheral blood (PB) based on their expression of CD33, CD13, and CD14. Whereas DC can be identified as CD33+ CD14dim or CD13+CD14dim cells, monocytes can be identified as CD33+CD14bright or CD13+CD14bright cells. Rheumatoid synovial fluid (SF) and synovial tissue (ST) non-T cells were found to be enriched in CD33+CD14dim cells compared with PB. Whereas 4 to 14% of normal or rheumatoid PB non-T cells were CD33+ and CD14dim, in rheumatoid SF or ST these cells comprised 20 to 45% of non-T mononuclear cells. Synovial CD33+CD14dim cells assumed a typical dendritic morphology on in vitro culture. Freshly isolated CD33+CD14dim PB DC precursors express low levels of HLA-DQ, CD40, and B7, which increase after in vitro incubation. In contrast, freshly isolated SF DC constitutively expressed these markers, and increased densities of HLA-DR and MHC class I molecules. Rheumatoid SF DC showed a specifically enhanced ability to stimulate autologous PB T cells compared with PB DC, or PB or SF monocytes. PB DC or monocytes preincubated in granulocyte-macrophage-CSF, TNF-alpha, or both cytokines exhibited enhanced expression of HLA-DR. Furthermore, DC preincubated in both granulocyte-macrophage-CSF and TNF-alpha were better stimulators of the autologous MLR than DC preincubated in medium, or in either cytokine alone. The data indicate that DC are enriched in rheumatoid SF and ST, and display a more differentiated phenotype than PB DC. These results suggest that PB DC accumulate in the synovium where they undergo phenotypic and functional differentiation in situ, which may be mediated by local cytokines. DC may play an important role in the ongoing presentation of antigen to autoreactive T cells in RA synovium.
Expression of v-src in T cells correlates with nuclear expression of NF-kappa B.
Authors: Eicher D M , Tan T H , Rice N R , O'Shea J J , Kennedy I C 
Published: December 2022

Abstract
NF-kappa B is a rapidly inducible transcriptional activator that responds to a variety of signals and influences the expression of many genes involved in the immune response. Protein tyrosine kinases transmit signals from cytokine and immune receptors. Very little information exists linking these two important classes of signaling molecules. We now demonstrate that v-src expression correlates with nuclear expression of a kappa B binding complex similar to that induced by phorbol ester and ionomycin, as detected by electrophoretic mobility shift assay using a variety of kappa B sites. This complex was blocked by the tyrosine kinase inhibitor, herbimycin A. The v-src-induced complex comprised the p50 and p65 components of NF-kappa B, as determined by supershift and immunoblot analysis. As a functional correlate of this finding, transient co-transfection of HIV-1 LTR reporter constructs in a different T cell line demonstrated that v-src activated this promoter in a kappa B-dependent manner. We found that transactivation of the HIV-1 LTR by v-src was more sensitive to mutations of the proximal, rather than the distal, kappa B element. The implications for T cell receptor signaling and HIV-1 gene expression are considered.
Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.
Authors: Majeau G R , Meier W , Jimmo B , Kioussis D , Hochman P S 
Published: December 2022

Abstract
Soluble ligands specific for cell surface molecules involved in APC-T cell interactions can signal cells and modulate immune responses. Recently, we reported that LFA3TIP, a fusion protein comprised of the first LFA-3 extracellular domain fused to the hinge, CH2, and CH3 regions of a human IgG1 inhibits proliferation of human T cells in vitro. We report herein the cell-based mechanism(s) of LFA3TIP in inhibition by studying the effects of structurally altered LFA3-Ig fusion proteins on proliferation of human PBL in vitro and on responses of mice transgenic for human CD2. We show that LFA3TIP inhibition requires expression of both the LFA-3 and CH2 domains of the fusion protein that bind CD2 and Fc gamma RI or Fc gamma RIII, respectively. LFA3TIP forms an intracellular Fc gamma R/CD2 bridge and directs cytolysis of CD2+ cells by freshly drawn human PBL in vitro as well as the non-C-mediated depletion of peripheral T cells of human CD2 transgenic mice. The cell-based mechanism(s) of LFA3TIP inhibition are discussed.
Generation and characterization of a monoclonal antibody that inhibits stromal cell-dependent B lymphopoiesis.
Authors: Nagasawa T , Kaisho T , Kishimoto T , Kikutani H 
Published: December 2022

Abstract
We generated a mAb, R4, against a stromal cell line, ST2, which is one of several stromal cell lines that can support in vitro B lymphopoiesis. Flow cytometry studies using R4 revealed that R4 reacted with several stromal, fibroblast, and some B cell lines, but not with freshly isolated bone marrow cells, splenocytes, thymocytes, or T cell lines. R4 could immunoprecipitate a M(r) = 24-kDa protein (p24) and a M(r) = 55-kDa protein (p55) from a stromal cell line and a B cell line, respectively. R4 inhibited the development of B cell progenitors from bone marrow cells in cultures supported by stromal cell lines, ST2, or op/op fibroblast line, but did not inhibit myelopoiesis supported by ST2. R4 also inhibited the growth of a stromal cell-dependent pre-B cell line, DW8, but not of two stromal cell-independent B cell lines, 70Z/3 and M12, despite the fact that R4 reacted all three of these lines. Because R4 inhibited B lymphopoiesis in the transwell culture where stromal cells are not allowed to contact pre-B cells, R4 Ag may not directly affect cellular contact. In vivo treatment of pregnant mice with R4 caused a reduction in the number of B cell progenitors in the bone marrows of some of the newborn offspring.
Point mutations define a mIgM transmembrane region motif that determines intersubunit signal transduction in the antigen receptor.
Authors: Pleiman C M , Chien N C , Cambier J C 
Published: December 2022

Abstract
Ag binding to the membrane Ig (mIg) substructure of the B cell Ag receptor leads to activation of cytoplasmic effector molecules including blk, fyn, lyn, and/or lck tyrosine kinases that are associated with receptor's dimeric Ig-alpha/Ig-beta transducer substructure. The structural basis of the apparent intermolecular transmission of this information within the receptor complex is unknown. Here we report that conservative point mutation of a sequence, S584-K597, at the cytoplasmic end of the predicted transmembrane spanning domain of the mIgM heavy chain (mu) ablates Ag-activated signal transduction, while having no detectable effect on association of mIgM with Ig-alpha/Ig-beta heterodimers. Specifically, mutation of serine584 to alanine, tyrosine587 to phenylalanine, threonine592 to valine, or lysine597 to isoleucine completely abrogated Ag-induced signal transduction leading to protein tyrosine phosphorylation and Ca2+ mobilization. Interestingly, mutants in the more peripheral of these residues, serine584 to alanine and lysine597 to isoleucine, remained responsive to a monoclonal antireceptor Ab (b-7-6) and all mutants remained responsive to polyclonal antireceptor Ab. These data implicate the polar sequence, -Y587STTVT592-, in transfer of information from ligand binding to transducer substructures within this heterooligomeric receptor complex. They further indicate that receptor activation by ligands that bind with high affinity and/or to constant region mIg epitopes is less dependent on the integrity of this motif.
Unique selection determinant in polyclonal V delta 2-J delta 1 junctional regions of human peripheral gamma delta T lymphocytes.
Authors: Breit T M , Wolvers-Tettero I L , van Dongen J J 
Published: December 2022

Abstract
Human peripheral gamma delta T lymphocytes are characterized by the preferential expression of a TCR consisting of a V delta 2-J delta 1-C delta chain and a V gamma 9-J gamma 1.2-C gamma 1 chain, which are virtually absent on thymocytes. Here we report the identification of a unique selection determinant that is located in the polyclonal V delta 2-J delta 1 junctional regions of peripheral gamma delta T lymphocytes. The selection determinant was discovered by the presence of an invariant T nucleotide at the relative second position of the V delta 2-J delta 1 junctional regions of peripheral polyclonal gamma delta T lymphocytes. Comparison of published sequences from peripheral gamma delta T lymphocytes confirmed the presence of this invariant T nucleotide (90%) in healthy individuals and in patients with various diseases. Translation of the relative first codon of the V delta 2-J delta 1 junctional regions revealed strikingly high frequencies of the homologous hydrophobic amino acids leucine (46%), valine (35%), and isoleucine (5%) at this position. The invariant T nucleotide was absent in polyclonal thymocytes and out-of-frame V delta 2-J delta 1 junctional regions, which proves that selection occurred at the protein level and not at the genomic level. No selection determinant could be identified in V gamma 9-J gamma 1.2 junctional regions, but the frequently occurring invariable, so-called canonical junctional region provided evidence for biased recombination processes. Although the obtained data do not allow discrimination between thymic selection and/or peripheral Ag-driven expansion, the identification of a strong selection determinant consisting of only one amino acid at a fixed position in V delta 2-J delta 1 junctional regions of virtually all peripheral polyclonal V delta 2/V gamma 9 T lymphocytes provides a new perception of TCR specificity and selection processes at the TCR protein level.
The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line epsilon transcription.
Authors: Liao F , Birshtein B K , Busslinger M , Rothman P 
Published: December 2022

Abstract
Treatment of murine splenic B lymphocytes and certain B-lineage cell lines with mitogen (LPS) and the lymphokine IL-4 has been shown to induce expression of germ-line epsilon transcripts (l epsilon transcripts) and class switching to the C epsilon gene. Three protein complexes, one of which (complex 3) is constitutively expressed, have been shown to bind to a 179-base pair LPS/IL-4-responsive l epsilon promoter (Rothman, P., S. C. Li, B. Gorham, L. Glimcher, F. W. Alt, and M. Boothby. 1991. Mol. Cell. Biol. 11:5551). Complex 3 is indispensable for this inducible promoter activity. In this report, we have used electrophoretic mobility shift assays (EMSA) to demonstrate that the early B cell-specific transcription factor (BSAP) is involved in the formation of complex 3. In addition, BSAP is implicated functionally in l epsilon transcription because a BSAP binding site either from a sea urchin histone promoter (H2A-2.2) or from 5' of murine immunoglobulin S gamma 2a can substitute for the epsilon-associated site (epsilon(foot), as assayed by transient transfection assays of the l epsilon:CAT reporter constructs into the M12.4.1 B cell line. Like the sea urchin histone BSAP site, the complex 3 binding site (epsilon(foot)) functions as an upstream promoter element when assayed in the OVEC vector. These results indicate that BSAP is an essential protein required for LPS/IL-4 induction of the l epsilon promoter. In addition, experiments showing that a BSAP binding site from 5' of S gamma 2a also functions as an upstream promoter element in OVEC suggest a potential role for BSAP in regulation of the IgG2a isotype.
A humanized antibody specific for the platelet integrin gpIIb/IIIa.
Authors: Co M S , Yano S , Hsu R K , Landolfi N F , Vasquez M , Cole M , Tso J T , Bringman T , Laird W , Hudson D 
Published: December 2022

Abstract
C4G1, a murine mAb reactive with the platelet gpIIb/IIIa integrin, was humanized for potential treatment of thrombosis-related disorders. The variable regions of light- and heavy-chain cDNAs from the C4G1 hybridoma were first cloned and sequenced. Humanized C4G1 Ab of the IgG1 isotype was constructed by combining the complementarity-determining regions of C4G1 with human framework and constant regions. The human framework was chosen to maximize homology with the C4G1 variable region sequence, and a computer model of C4G1 was used to aid design of the final framework sequence. Genetic constructs were also developed to produce Fab and F(ab')2 fragments of the humanized C4G1 Ab. The humanized IgG1 Ab as well as the Fab and F(ab')2 fragments showed equivalent binding affinities to their murine counterparts, indicating no loss in binding affinity during the humanization process. The humanized Ab and its fragments were also shown to inhibit platelet aggregation and to inhibit binding of fibrinogen to gpIIb/IIIa in vitro.
Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase.
Authors: Jeurissen F , Kavelaars A , Korstjens M , Broeke D , Franklin R A , Gelfand E W , Heijnen C J 
Published: December 2022

Abstract
The data presented in this paper demonstrate a new substance P (SP) binding site that is expressed on human monocytes. The apparent dissociation constant (Kd) for binding of 125I-labeled Bolton Hunter-SP (125I-BH-SP) to the receptor on monocyte membranes is 2.24 +/- 0.9 x 10(-7) M and the maximum binding capacity (Bmax) is 4.7 +/- 0.5 pmol/mg membrane protein. It could be excluded that this receptor is one of the known neurokinin (NK) type of receptors on the basis of binding characteristics for NK1, NK2, and NK3 agonists. Moreover, we demonstrate that the binding site is neither the bombesin receptor nor the serpin enzyme complex receptor nor the FMLP receptor. The order of potency for inhibition of 125I-BH-SP binding to the receptor on monocyte membranes is NK1 antagonist [D-Pro2,D-Trp7,9]SP &gt; SP &gt; NK3 agonist [MePhe7]SP &gt; bombesin. Cross-linking studies with disuccinimidylsuberate, followed by SDS-PAGE analysis, revealed that 125I-BH-SP is specifically bound to a membrane protein with an apparent molecular mass of 47 kDa. At a functional level, SP induces the activation of MAP kinase in human monocytes. The ED50 for activation of MAP kinase positively correlated (r = 0.999, p &lt; 0.0005) with the apparent affinity of the ligands applied in the 125I-BH-SP displacement studies. From these results, we conclude that this SP binding site on monocytes is a non-NK receptor protein that is functionally linked to the activation of MAP kinase.